TOT BIOPHARM International Co. Ltd. (HK:1875) has released an update.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
TOT BIOPHARM International Co. Ltd. reported a substantial 49% increase in revenue for the first nine months of 2024, reaching RMB809,021 thousand, driven by robust sales of its self-developed products and CDMO/CMO services. The company also turned profitable, posting a net profit of RMB35,403 thousand compared to a loss in the same period last year. Investors should note that the results are unaudited and may fluctuate in future periods.
For further insights into HK:1875 stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue